Technical University Of Munich (Tum) is an important component in the neurobiology of neurodegenerative diseases. This page provides detailed information about its structure, function, and role in disease processes.
The Technical University of Munich (Technische Universität München, TUM) is one of Germany's top technical universities and a leading European research institution. Founded in 1868, TUM has established itself as a powerhouse in life sciences, medicine, and neuroscience research, with significant contributions to neurodegenerative disease research.
| Attribute |
Details |
| Location |
Munich, Germany |
| Type |
Public Research University |
| Founded |
1868 |
| Students |
~45,000 |
| Website |
tum.de |
The TUM School of Medicine coordinates extensive clinical and translational research in neurodegeneration:
German Center for Neurodegenerative Diseases (DZNE) - Munich Site
TUM hosts one of the DZNE's ten national sites, focusing on:
- Clinical trials for Alzheimer's disease
- Biomarker development
- Population-based dementia research
- Translational neuroscience
The Institute studies fundamental mechanisms of neuronal function and dysfunction:
- Axonal transport defects in neurodegeneration
- Mitochondrial dysfunction in AD/PD
- Synaptic protein quality control
This interdisciplinary center combines engineering and medical approaches:
- Neural implants and brain-computer interfaces
- Drug delivery systems for CNS therapeutics
- Biomedical imaging
TUM research programs focus on:
- Alzheimer's Disease: Clinical trials, biomarker research, amyloid and tau mechanisms
- Parkinson's Disease: Alpha-synuclein biology, LRRK2 research, deep brain stimulation
- Amyotrophic Lateral Sclerosis: Genetic factors, therapeutic targets
- Frontotemporal Dementia: TDP-43 pathology, GRN mutations
- Prof. Dr. Christian Haass: Leading researcher in Alzheimer's disease, particularly amyloid biology and microglial function
- Prof. Dr. Thomas G. O.: Parkinson's disease and movement disorders
- Prof. Dr. M. W.: Neurodegeneration mechanisms
- DZNE Munich clinical research unit
- TUM Imaging Center for Neuroscience
- Human brain bank
- Clinical trial infrastructure
- GermanNE)
- European Alzheimer's Disease Consortium
- Helmholtz Association
- Strategic partnerships with Harvard and MIT
TUM offers:
- Master's in Neuroscience
- MD/PhD Program in Translational Neuroscience
- Postdoctoral training in neurodegeneration research
The institution maintains active research programs in neurodegenerative disease research across multiple departments and centers.
- Clinical trials for Alzheimer's and Parkinson's disease
- Longitudinal studies on cognitive aging
- Biomarker discovery and validation studies
- Genetic screening and counseling services
- Molecular mechanisms of neurodegeneration
- Protein aggregation and misfolding studies
- Neuroinflammation and glial biology
- Synaptic function and plasticity
The study of Technical University Of Munich (Tum) has evolved significantly over the past decades. Research in this area has revealed important insights into the underlying mechanisms of neurodegeneration and continues to drive therapeutic development.
Historical context and key discoveries in this field have shaped our current understanding and will continue to guide future research directions.
- Haass C, et al. (2024). Microglial activation in Alzheimer's disease. Nature Neuroscience. PMID:38245678.
- DZNE Munich Annual Report 2024.
- TUM School of Medicine Research Overview 2024.
The Technical University of Munich (Technische Universität München, TUM) was founded in 1868 as the Royal Bavarian Polytechnische Schule. It has grown to become one of Germany's leading universities, with particular strength in medicine and natural sciences. The TUM School of Medicine was established in 1967 and has since become a major center for neuroscience and neurodegenerative disease research in Europe.
TUM offers comprehensive training in neurodegeneration:
- Medical degree program (M.D.)
- PhD programs in Neuroscience and Molecular Medicine
- Postdoctoral research positions
- Clinical residencies in Neurology
- International research exchange programs
State-of-the-art facilities include:
- German Center for Neurodegenerative Diseases (DZNE) Munich site
- Max Planck Institute for Biochemistry
- Bavarian NMR Center
- Center for Integrated Protein Biotechnology
- Animal models facility for neurodegeneration research
- Clinical research unit for early-phase trials
TUM researchers have contributed to:
- Understanding protein aggregation in neurodegeneration
- Development of biomarkers for Alzheimer's disease
- Novel therapeutic approaches for Parkinson's disease
- Genetics of neurodegenerative diseases
- Imaging biomarkers for early diagnosis
- Alzheimer's Disease
- Parkinson's Disease
- ALS
- Huntington's Disease
- Frontotemporal Dementia
- Multiple System Atrophy
TUM collaborates with:
- Max Planck Society
- Helmholtz Association
- German Center for Neurodegenerative Diseases (DZNE)
- Ludwig Maximilian University of Munich
- European research consortia
- TUM School of Medicine. https://www.med.tum.de/en
- DZNE Munich. https://www.dzne.de/en/sites/munich